{"text": "Differences between the analytic sample and the excluded participants were generally small (Table S1 in Supplement 1).", "sentId": 1, "start": 0, "end": 118}
{"text": "Compared with those included, participants excluded from the analyses were more likely to be women, nonwhite, and current smokers, although other characteristics were similar in the two groups.", "sentId": 2, "start": 119, "end": 312}
{"text": "Across the 5-year data cycles, 12.1% of participants without GHQ symptoms developed such symptoms, 4.6% of those without CES-D depressive symptoms had such symptoms at follow-up, and 2.1% of those not on antidepressant treatment started such medication.", "sentId": 3, "start": 313, "end": 566}
{"text": "Of the cases of GHQ symptoms, 5.4% used antidepressant medication, the corresponding proportion being 9.2% for those with CES-D depressive symptoms.", "sentId": 4, "start": 567, "end": 715}
{"text": "Of participants with GHQ symptoms, 47.4% also had CES-D depressive symptoms (Pearson correlation at phase 7 r = .64, p < .001).", "sentId": 5, "start": 716, "end": 843}
{"text": "Conversely, among participants with CES-D depressive symptoms, 59.9% also had GHQ symptoms.", "sentId": 6, "start": 844, "end": 935}
